Printer Friendly

Biomarker Technologies' New Blood Test for Breast Cancer Seeks Future Test Candidates; Women and Physicians Needed for First-of-Kind Test.

PHOENIX -- Biomarker Technologies LLC, the worldwide technology provider of the BT Test(TM), is beginning a nationwide mobilization of women and physicians who want to become involved in upcoming clinical studies for this first-of-its-kind diagnostic blood test for breast cancer.

The company is seeking both healthy women and those with recently diagnosed breast cancer, as well as physicians who are interested in being contacted for more information. When new studies are launched, those who sign up will be contacted first with complete study details and requirements. The studies are part of the FDA Pre-Market Approval (PMA) process for the BT Test. The company is looking to submit data to the FDA in the near future.

The www.BiomarkerTech.com Web site also includes a confidential survey for both patients and physicians to express attitudes and opinions about the current diagnostic process for breast cancer. Since nearly 45% of women at risk in the United States do not get annual mammograms, survey participants are asked about their attitudes and preferences for a blood diagnostic test for breast cancer. The data will be used to create programs to educate women on the importance of getting tested annually for breast cancer.

"Our goal is to begin saving lives from this devastating disease," said William Gartner, CEO and president of Biomarker Technologies LLC. "The more women and physicians who express interest in the test via our Web site, the faster we can begin our clinical study for FDA approval and bring this remarkable blood test to market."

The company is in the final phase for its "blind" pilot study with 100 participants, which has been designed to enhance the method prior to undertaking final FDA clinical studies. In previous studies, the BT Test successfully identified over 95% of the non-treated breast cancer in women as compared to mammography's performance at 80% (on average).

"This combination of comfort and accuracy gives the BT Test the potential to save tens of thousands of women's lives annually by detecting breast cancer at the earliest stages," said Gartner.

Breast Cancer Facts

--Breast cancer is the most common form of cancer in women, striking one out of every seven women. However, with early detection, the five-year survival rate is about 97% when the cancer has not spread at the time of diagnosis.

--The American Cancer Society Inc. (ACS) estimates that approximately 45,000,000 mammograms were conducted in 2004. In 2005, ACS estimates that more than 211,000 new cases of breast cancer will be diagnosed and 40,410 women will die of the disease in the United States alone (more than 376,000 worldwide).

--Additionally, ACS estimates 45% of women over 40 years of age do not get their annual mammogram as recommended because of the fear, pain and/or anxiety associated with the procedure.

About the BT Test

The BT Test is designed to detect the presence of breast cancer at the molecular level unlike mammography, which only detects masses or gross changes in breast tissue via X-ray imaging. The BT Test is an IP protected blood test that offers women a more comfortable test method and greater convenience while providing caregivers higher sensitivity, early detection capabilities, broader range of age applicability and ease of administration. The test measures five key cancer-associated biomarkers and when combined and adjusted for age, has shown the potential to detect early stage breast cancer.

About Biomarker Technologies LLC

Biomarker Technologies LLC is a translational in-vitro diagnostic company focused on breast cancer. The company is poised to bring the BT Test to market as fast as possible with both U.S. and global approvals. Founded by William Gartner, president and CEO, and Everett Warren, chairman, Biomarker Technologies is located at 1440 E. Missouri Ave., Suite 225, Phoenix, AZ 85014 and can be reached at 602-468-0067. For more information about the company and the BT Test, visit www.biomarkertech.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 3, 2005
Words:647
Previous Article:SIPAC Becomes OCP-IP Member and Helps Launch Korean Language Website; New Website Allows Korean Members to Access Material in Their Local Language.
Next Article:Home Photo Printer Market Booming: Up Almost $400 Million in 2004, InfoTrends/CAP Ventures Study Says.


Related Articles
Blocking breast cancer: do faulty estrogen receptors make a meaner, tougher tumor?
Does gene hike radiation's cancer risk.
Homing in on inherited breast cancer genes.
Marrow Can Hide Breast Cancer Cells.
QUESTIONS FREQUENTLY ASKED BY WOMEN WITH IMPLANTS.
CANCER TREATMENT DRAWS NOTICE; SANTA CLARITA CENTER RECEIVING NUMEROUS INQUIRIES.
BREAST CANCER RESEARCH PAYING DIVIDENDS; TWO NEW DRUGS OFFER EXCITING POSSIBILITIES, COMPLEXITIES.
STUDY GAUGES BENEFITS OF MASTECTOMIES.
UTAH FIRM TO PROVIDE NEW TESTING TO SCREEN FOR BREAST, OVARIAN CANCER.
Ominous signals: genes may identify the worst breast cancers. (This Week).

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters